Chemotherapeutic drugs and human tumor cells cytokine network
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The ability of human tumor cell lines to produce various cytokines, chemokines, angiogenic and growth factors was investigated using Luminex multiplex technology. Media conditioned by tumor cells protected tumor cells from drug‐induced apoptosis and stimulated tumor cell proliferation. Antibodies neutralizing IL‐6, CXCL8, CCL2 and CCL5 blocked this stimulation. Treatment of tumor cells with doxorubicin and cisplatin resulted in a substantial increase in the production of IL‐6, CXCL8, CCL2, CCL5, BFGF, G‐CSF and VEGF. This stimulation was associated with drug‐induced activation of NF‐κB, AP‐1, AP‐2, CREB, HIF‐1, STAT‐1, STAT‐3, STAT‐5 and ATF‐2 transcription factors and upregulation of IL‐6, CXCL8, FGF‐2, CSF‐3 and CCL5 gene expression. Treatment of tumor cells with doxorubicin and antibodies neutralizing G‐CSF, CCL2 or CCL5 had higher inhibitory effects than each modality used alone. These results indicate that chemokines and growth factors produced by tumor by binding to the cognate receptors on tumor and stroma cells could provide proliferative and antiapoptotic signals helping tumor to escape drug‐mediated destruction. Clinical studies showed that antibodies neutralizing VEGF (Avastin/Bevacizumab) or blocking HER2/neu signaling (Herceptin/Trastuzumab) could increase the efficacy of chemotherapy, although these beneficial effects have been limited. It is possible that drug‐stimulated production of growth and proangiogenic factors could counterbalance the effects of antibody therapy. In addition, numerous growth factors and chemokines share angiogenic and growth‐stimulating properties, and thus reduction of a single factor is insufficient to completely block tumor growth. Thus, a broad disruption of tumor cytokine network is needed to further increase the efficacy of cancer therapy. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135 · cited 1×
“In addition, IL-8 exhibits strong angiogenic activity.(13,16,17) Chemokines of the CC superfamily such as CCL5 (RANTES) and CCL2 (MCP-1) also are able to stimulate migration of normal and malignant cells, as well as promote tumor angiogenesis.”
BackgroundClinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004 · cited 1×
“Tumor-produced VEGF is the most potent angiogenic factor, which stimulates migration and proliferation of endothelial cells and formation of blood vessels.(2,3) Malignant transformation is often associated with overexpression of various growth factors including FGF, EGF and HGF, all of which stimulate proliferation of…”
BackgroundTransforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792
Research works printed but not linked: 49
- 10.1016/S0065-230X(05)93005-4 · DOI
- 10.1038/nrc905 · DOI · Paper page
- 10.1016/S0065-230X(08)60305-X · DOI · Paper page
- 10.1078/0171-9335-00349 · DOI
- 10.1083/jcb.141.7.1659 · DOI · Paper page
- 10.1016/S0002-9440(10)64058-8 · DOI · Paper page
- 10.1083/jcb.129.5.1177 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-0623 · DOI · Paper page
- 10.1016/S0140-6736(94)90387-5 · doi:10.1016/s0140-6736(94)90387-5
- 10.1182/blood.V95.8.2630 · DOI · Paper page
- 10.1002/ijc.10833 · DOI · Paper page
- 10.1159/000028045 · DOI · Paper page
- 10.1080/13684730050515868 · DOI
- Xu L, 2000, Interleukin 8: an autocrine growth factor for human ovarian cancer, Oncol Res, 12, 97, 10.3727/096504001108747567 · DOI
- 10.1016/j.ejca.2006.01.006 · DOI · Paper page
- Azenshtein E, 2002, The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity, Cancer Res, 62, 1093
- 10.1007/s10555-006-9003-5 · DOI · Paper page
- 10.1182/blood.V96.1.34 · DOI · Paper page
- 10.1016/j.semcancer.2003.10.006 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-0074 · DOI · Paper page
- 10.1007/BF02785841 · DOI
- 10.1158/1078-0432.CCR-04-0812 · DOI · Paper page
- 10.1016/0002-9378(91)90582-C · DOI · Paper page
- Schneider GP, 2001, The diverse role of chemokines in tumor progression: prospects for intervention (Review), Int J Mol Med, 8, 235
- 10.1016/j.bbrc.2005.05.132 · DOI · Paper page
- 10.1056/NEJMoa052122 · DOI · Paper page
- 10.1200/JCO.2004.11.070 · DOI
- Lev DC, 2003, Dacarbazine causes transcriptional up‐regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy, Mol Cancer Ther, 2, 753
- 10.4049/jimmunol.172.10.6330 · doi:10.4049/jimmunol.172.10.6330
- 10.1002/ijc.10842 · DOI
- 10.1089/154065803322302826 · DOI · Paper page
- 10.1158/1055-9965.EPI-04-0404 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-1805 · DOI · Paper page
- 10.1089/adt.2006.4.293 · DOI
- 10.1002/mc.20217 · DOI · Paper page
- 10.1038/nri887 · DOI · Paper page
- 10.1016/S1054-3589(08)60111-8 · DOI · Paper page
- 10.1038/sj.onc.1204383 · DOI · Paper page
- 10.1172/JCI25740 · DOI · Paper page
- 10.1002/pros.20306 · DOI · Paper page
- 10.1038/sj.bjc.6690164 · DOI · Paper page
- Choi C, 2001, Fas‐induced expression of chemokines in human glioma cells: involvement of extracellular signal‐regulated kinase 1/2 and p38 mitogen‐activated protein kinase, Cancer Res, 61, 3084
- 10.1016/j.yexcr.2007.12.027 · DOI
- 10.1073/pnas.0402048101 · DOI
- 10.4049/jimmunol.172.9.5467 · DOI · Paper page
- 10.1002/ijc.23324 · DOI
- Talapatra S, 2001, Growth factor signaling in cell survival: implications for cancer treatment, J Pharmacol Exp Ther, 298, 873, 10.1016/S0022-3565(24)29451-9 · DOI
- 10.1038/nrc1650 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-0905 · DOI · Paper page
Cited by
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties
Levina, V., Marrangoni, A. M., DeMarco, R., Gorelik, E., & Lokshin, A. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003077 · Cited by 407
Self-citationWan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295
Aldinucci, D., Gloghini, A., Pinto, A., De Filippi, R., & Carbone, A. (2010) · The Journal of Pathology · doi:10.1002/path.2711 · Cited by 275
Levina, V., Marrangoni, A., Wang, T., Parikh, S., Su, Y., Herberman, R., Lokshin, A., & Gorelik, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1102 · Cited by 155
Self-citationp53 is an important regulator of CCL2 gene expression
Tang, X., Asano, M., O’Reilly, A., Farquhar, A., Yang, Y., & Amar, S. (2012) · Current Molecular Medicine · doi:10.2174/156652412802480844 · Cited by 30
“As CCL2 is associated with a variety of disorders, several regulatory factors have been found to affect its production, such as enhancers AP-1, AP-2beta, STAT6, NFκB [49-51], TNF-α [52], Tat [53], LPS [54], S1P [55], and Nef [56].”
Background
Metadata
- Authors
- Levina, V., Su, Y., Nolen, B., Liu, X., Gordin, Y., Lee, M., Lokshin, A., & Gorelik, E.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-08-25
- Volume
- 123
- Issue
- 9
- Pages
- 2031-2040
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2051043829
- Cited by
- 90
- References
- 3
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.